Vertex Pharmaceuticals Inc (VRTX)

213.35 +3.07  +1.46% NASDAQ Apr 9, 20:00 USD

Vertex Pharmaceuticals Income Statement (Quarterly)

Export Data

December 2020 - September 2018

Previous Periods

Income (Quarterly) 2020-12 2020-09 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09
Operating Revenue Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Revenue 1.628B 1.538B 1.524B 1.515B 1.413B 949.83M 941.29M 858.44M 870.11M 784.54M
Cost of Goods Sold Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gross Profit 1.425B 1.352B 1.340B 1.353B 1.228B 817.91M 805.55M 763.34M 747.82M 673.28M
SG&A Expense 211.84M 184.55M 191.80M 182.26M 195.28M 159.67M 156.50M 147.04M 153.21M 137.30M
Research and Development Expense 466.58M 493.50M 420.93M 448.53M 480.01M 555.95M 379.09M 339.49M 437.88M 330.51M
Income Statement Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Amortization Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Special Income and Charges Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Non-Operating Interest Income Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Income and Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Pre-Tax Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Provision for Income Taxes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Extraordinary Items, Income Statement Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income Attributable to Minority Interest Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Income 604.19M 667.43M 837.27M 602.75M 583.23M 57.52M 267.43M 268.63M 1.551B 128.75M
Normalized Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBITDA Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Reconciled Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBIT Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Basic EPS (Quarterly) 2020-12 2020-09 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09
EPS Basic from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Extraordinaries Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Basic EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Diluted EPS (Quarterly) 2020-12 2020-09 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09
EPS Diluted from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Extraordinaries Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Diluted EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted 2.30 2.53 3.18 2.29 2.23 0.22 1.03 1.03 5.97 0.50
Shares Data (Quarterly) 2020-12 2020-09 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09
Average Basic Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Average Diluted Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SEC Filing Links 2020-12 2020-09 2020-06 2020-03 2019-12 2019-09 2019-06 2019-03 2018-12 2018-09
As Originally Reported AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR
Restated Restated Restated Restated Restated Restated Restated

December 2020 - September 2018

Previous Periods

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.